acute ecxacerbation of chronic obstroctive lung disease. Chronic obstructive pulmonary disease with acute exacerbation, unspecified
Conditions
Interventions
Intervention 1: control group recieves standard therapy. Intervention 2: Intervention group recieve vitamin D 300,000 IU intramuscullaryin addition to standard therapy of AECOPD.
Treatment - Drugs
control group recieves standard therapy
Intervention group recieve vitamin D 300,000 IU intramuscullaryin addition to standard therapy of AECOPD
Sponsors
Research council of School of Pharmacy, Shahid Beheshti University
Eligibility
Sex/Gender
All
Age
40 Years to 139 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria include; Vitamin D deficiency (serum 25(OH)D < 50 nmol/l) ? Postbronchodilator FEV1/FVC < 0.70, FEV1< 80 % and diagnosis acute exacerbation of COPD confirmed by a physician Age=40 years ? Written informed consent ? Ability to comply with all study requirements Exclusion criteria include Severe vitamin D deficiency (serum 25(OH)D <15 nmol/l),? Use of a supplement containing more than 400 IU vitamin D per day Diagnosed asthma Diagnosed osteoporosis Self-reported history of hypercalcaemia or nephrolithiasis Self-reported presence of sarcoidosis Diagnosed chronic kidney disease stage 4 or higher (eGFR=29 ml/min/1.73 m2)? liver insufficiency child pough class B or C Interfering malignant diseases Life expectation of less than 1 year on the basis of concurrent disease Current participation in a clinical rehabilitation program Pregnant or lactating women, or subjects who intend to become pregnant within the study period Potentially unreliable patients and those judged by the investigator to be unsuitable for the study Serious mental impairment i.e. preventing to understand the study protocol or comply with the study aim.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin 6 and interleukin 8 and hsCRP LEVEL. Timepoint: day of admision and day 5. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Modified medical research council dyspnea scale. Timepoint: day of admision-day 5 and mounth 3 after inclusion to study. Method of measurement: questionaire.;St george respiratory questionnaire quality of life. Timepoint: day 1 and 90 after admission. Method of measurement: Patient-reported Outcomes & questionnaire fill out. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactdr Seyed mouhmad hassn pourrashid
faculty of pharmacy Shahid Beheshti University of Medical Sciences
Outcome results
None listed